Wilson / Novartis Pharma AG / Astrophysics Research Corporation / Slm / Bio-Rad / Bernstein / Stephens / Elsevier Inc. / /
Currency
pence / / /
Event
FDA Phase / Product Issues / /
Facility
University of Basel / Rad53 checkpoint / TOR complex / TORC2 complex / University of Geneva / Miescher Institute / TORC1 complex / M. Hall / Mec1-Ddc2 complex / /
IndustryTerm
active site / inhibition protocol / catalytic site / putative active site / Reaction products / fluorescence imaging / cytotoxic natural product / /
MedicalCondition
ataxia telangiectasia / tumor / lack of coordination / cancer / strain / DNA damage hypersensitivity / tumour / extreme hypersensitivity / mammalian cancer / pancreatic cancer / glioblastoma / Zeocin hypersensitivity / certain cancer / /
University of Basel / University of Geneva / DNA Strand Breaks Kenji Shimada / 1 / 5 Ireos Filipuzzi / 2 / 5 Michael Stahl / 3 Stephen B. Helliwell / 2 Christian Studer / 2 Dominic Hoepfner / 2 Andrew Seeber / 1 / 4 Robbie Loewith / 3 N. Rao Movva / 2 and Susan M. Gasser1 / 4 / * 1Friedrich Miescher Institute for Biomedical Research / European Research Council / Swiss National Science Foundation / Novartis Research Foundation / /
Molecular Cell Short Article TORC2 Signaling Pathway Guarantees Genome Stability in the Face of DNA Strand Breaks